Welcome to our dedicated page for Prelude Therapeutics news (Ticker: PRLD), a resource for investors and traders seeking the latest updates and insights on Prelude Therapeutics stock.
Prelude Therapeutics Incorporated (Nasdaq: PRLD) is a clinical-stage precision oncology company, and its news flow reflects the progress and risks of early-stage cancer drug development. Company announcements frequently cover updates on highly selective SMARCA2 degraders, oral KAT6A degraders, a mutant selective JAK2V617F JH2 inhibitor program for myeloproliferative neoplasms, and mutant CALR-targeted degrader antibody conjugates (DACs).
Investors and researchers following PRLD news can expect regular reports on clinical trial milestones, such as Phase 1 dose-escalation progress for PRT7732, completion of Phase 1 studies for PRT3789, and plans for Phase 2 combinations with agents like pembrolizumab. Press releases also summarize preclinical data presented at major medical meetings, including the American Association for Cancer Research, the American Society of Hematology, European Hematology Association, and other oncology-focused conferences.
Prelude’s news often highlights strategic portfolio decisions, for example prioritizing KAT6A and JAK2V617F programs, pausing further clinical development of certain SMARCA2 programs, and expanding collaborations. Announcements have detailed an exclusive option agreement with Incyte for the JAK2V617F program and an expanded collaboration with AbCellera Biologics around degrader payloads for precision DACs.
In addition, PRLD news includes quarterly financial results, cash runway commentary, and governance updates such as board appointments and leadership changes. For those tracking precision oncology and targeted protein degradation, this news stream provides insight into Prelude’s evolving pipeline, partnership activity, and regulatory and listing developments. Bookmark this page to review the latest earnings releases, scientific data disclosures, and corporate updates related to Prelude Therapeutics stock.
Prelude Therapeutics (Nasdaq: PRLD) has initiated a public offering of 1,750,000 shares of common stock under a filed registration statement. The company will sell all shares, with a potential 30-day option for underwriters to purchase up to an additional 262,500 shares. The offering is led by Morgan Stanley, Goldman Sachs, BofA Securities, and Barclays. Completion of the offering is not guaranteed, as the registration statement with the SEC has yet to become effective, and no sales can occur until it does.
Prelude Therapeutics completed its IPO, raising approximately $181.9 million. The company reported a net loss of $16.8 million for Q3 2020, an increase from $6.7 million in Q3 2019. Clinical updates include a partial response in a glioblastoma multiforme patient during the PRT811 trial and a durable complete response in an ovarian cancer patient in the PRT543 trial. Prelude's cash and equivalents stood at $234.8 million as of September 30, 2020, indicating robust financial positioning for upcoming clinical trials.
Prelude Therapeutics has priced its initial public offering of 8,325,000 shares at $19.00 per share, aiming for gross proceeds of approximately $158.2 million. The offering will close on September 29, 2020, and shares are set to trade on the Nasdaq under the ticker PRLD starting September 25, 2020. An additional 1,248,750 shares may also be purchased by underwriters within 30 days. Morgan Stanley, Goldman Sachs & Co. LLC, and BofA Securities are managing the offering.